Patrick Yeramian
Corporate Officer/Principal at Dlx Therapeutics L L C
Net worth: 353 641 $ as of 30/05/2024
Patrick Yeramian active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Dlx Therapeutics L L C | Corporate Officer/Principal | 31/12/2017 | - |
Career history of Patrick Yeramian
Former positions of Patrick Yeramian
| Companies | Position | Start | End |
|---|---|---|---|
| AMYLYX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 28/02/2019 | 27/11/2023 |
| BIOVIE INC. | Chief Tech/Sci/R&D Officer | 31/10/2018 | 31/10/2021 |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Chief Tech/Sci/R&D Officer | 28/02/2017 | 28/02/2019 |
| MARKER THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/01/2015 | 31/12/2016 |
| Tapimmune, Inc. | Chief Tech/Sci/R&D Officer | 31/01/2015 | 31/12/2016 |
Vaccine & Gene Therapy Institute of Florida Corp.
 Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Vaccine & Gene Therapy Institute of Florida Corp. provides research services. The non-profit company is based in Port Saint Lucie, FL. | Chief Tech/Sci/R&D Officer | 30/09/2011 | 31/01/2015 |
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Chief Tech/Sci/R&D Officer | 31/05/1998 | 31/05/2001 |
| G.D. Searle LLC | Corporate Officer/Principal | 31/05/1993 | 31/05/1998 |
| ░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
Training of Patrick Yeramian
| Universite Paris Est Creteil Val De Marne | Doctorate Degree |
| Rutgers Business School | Masters Business Admin |
Statistics
International
| United States | 12 |
| France | 3 |
Operational
| Chief Tech/Sci/R&D Officer | 8 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 4 |
| Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| MARKER THERAPEUTICS, INC. | Health Technology |
| BIOVIE INC. | Health Technology |
| AMYLYX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Viragen, Inc.
Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Health Technology |
| Université de Paris XI Paris Sud | Consumer Services |
| G.D. Searle LLC | |
Vaccine & Gene Therapy Institute of Florida Corp.
Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Vaccine & Gene Therapy Institute of Florida Corp. provides research services. The non-profit company is based in Port Saint Lucie, FL. | Commercial Services |
Kantum Pharma, Inc.
Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Commercial Services |
| Dlx Therapeutics L L C | |
| Tapimmune, Inc. |
- Stock Market
- Insiders
- Patrick Yeramian
- Experience
